-
2024-511171-15-00
3
2020-07-06
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
-
2022-502482-17-00
5
2020-05-19
Non-small cell lung cancer (NSCLC)
-
2024-514471-18-00
5
2020-05-13
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
-
2024-513032-14-00
4
2020-04-21
Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
-
2024-516972-14-00
4
2020-01-30
Hepatocellular carcinoma
-
2022-503050-39-00
5
2019-11-12
Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-512352-38-00
4
2019-03-28
Hepatitis B, Chronic
-
2023-503587-17-00
9
2019-03-20
Hematologic malignancies
-
2023-508655-39-00
7
2019-02-13
Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
-
2023-508343-48-00
5
2019-01-25
Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
-
2023-503554-12-00
9
2019-01-09
lung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer;
-
2022-500990-16-00
4
2018-12-19
Stage IV non-small cell lung cancer
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2024-511553-22-00
5
2018-10-05
Moderately to Severely Active Crohn's Disease
-
2023-510426-33-00
5
2018-09-27
Moderately to Severely Active Crohn's Disease
-
2024-511533-35-00
4
2018-09-03
Mantle Cell Lymphoma
-
2023-506564-14-00
1
2018-05-16
Relapsed and refractory multiple myeloma (RRMM)
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2024-511660-89-00
4
2017-06-09
metastatic castration resistant prostate cancer (mCRPC)
-
2022-500400-22-00
5
2016-06-23
Hodgkin lymphoma
-
2024-514815-92-00
5
2015-07-16
Ulcerative colitis
-
2024-517856-36-00
5
2015-03-09
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce